Actively Recruiting
Comparing Two Oral Formulations of HRS-1893 Tablets in Healthy Adults Aged 18 to 55 Years Phase 1 Randomized Crossover Study
Led by Shandong Suncadia Medicine Co., Ltd. · Updated on 2026-06-29
58
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the bioequivalence between two formulations of HRS-1893 tablets in healthy adults aged 18 to 55 years. The study aims to compare how the body absorbs and processes each formulation, while also assessing their safety and tolerability. This phase 1 trial is sponsored by Shandong Suncadia Medicine Co., Ltd. and uses a randomized crossover design. Participants will receive both the test and reference formulations of HRS-1893 tablets orally during different periods of the study. The study evaluates peak concentration, area under the plasma concentration-time curve, time to peak concentration, elimination half-life, and other pharmacokinetic measures from Day 1 to Day 17. Safety assessments include monitoring adverse events, ECG, echocardiogram, and vital signs up to Day 21
CONDITIONS
Brief Title
A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants
Research Team
W
Wenzheng Xiong
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
